Pharmacokinetic study of chloramphenicol in patients with liver disease

Eur J Clin Pharmacol. 1981;20(6):479-83. doi: 10.1007/BF00542103.

Abstract

The pharmacokinetics of intravenous chloramphenicol has been studied in 42 patients with liver disease and in 8 controls. The half-life of chloramphenicol (t 1/2) was increased in the various liver disorders, the metabolic clearance rate (MCR) and apparent volume of distribution (Vd) were decreased and the area under the time - concentrations curve (AUC) showed an increase. The t 1/2 of chloramphenicol showed a significant correlation with serum albumin and prothrombin time index.

MeSH terms

  • Acute Disease
  • Adult
  • Budd-Chiari Syndrome / metabolism
  • Chloramphenicol / blood
  • Chloramphenicol / metabolism*
  • Female
  • Half-Life
  • Hepatitis / metabolism
  • Humans
  • Hypertension, Portal / metabolism
  • Kinetics
  • Liver Abscess, Amebic / metabolism
  • Liver Cirrhosis / metabolism
  • Liver Diseases / metabolism*
  • Liver Function Tests
  • Male
  • Portal Vein
  • Vascular Diseases / metabolism

Substances

  • Chloramphenicol